Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 96,400 shares, a growth of 41.3% from the March 31st total of 68,200 shares. Based on an average daily volume of 841,900 shares, the short-interest ratio is currently 0.1 days. Currently, 4.3% of the shares of the stock are short sold.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 76.14% of the company’s stock.

Galmed Pharmaceuticals Stock Performance

Galmed Pharmaceuticals stock opened at $1.25 on Friday. Galmed Pharmaceuticals has a fifty-two week low of $1.15 and a fifty-two week high of $23.80. The stock has a market cap of $2.07 million, a P/E ratio of -0.08 and a beta of 0.70. The firm’s fifty day moving average price is $1.67 and its 200-day moving average price is $2.56.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on GLMD shares. Maxim Group reissued a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday, April 4th. StockNews.com initiated coverage on Galmed Pharmaceuticals in a research report on Tuesday. They set a “sell” rating for the company.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.